Lu-DOTA-TATE not checked

Novartis Pharmaceuticals · Lutetium Lu 177 dotatate

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1/2 trial completes
Trials
10 active
12 in total · 12 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)”In the company’s words, NCT04711135 on ClinicalTrials.gov
Tested for
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma, Extensive Stage Small Cell Lung Cancer, Glioblastoma
Main trialPhase 2
“This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.”In the company’s words, NCT04711135 on ClinicalTrials.gov
Other names
Lutathera · Lutetium Lu 177 dotatate · Lutetium oxodotreotide/dotatate

Other drugs for Gastroenteropancreatic Neuroendocrine Tumors

All 8 drugs for Gastroenteropancreatic Neuroendocrine Tumors

Coming up1

Changes2

Last 90 days

Trials12

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 12 Mar 2024 Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Phase 1/2Active, not recruiting 7 Mar 2028 A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Phase 1Active, not recruiting 3 Dec 2025 A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Phase 1Terminated 16 Oct 2026 NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Phase 2Authorised not given A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N
Phase 2Authorised not given A PROSPECTIVE RANDOMIZED PHASE II STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® ([177LU]LU-DOTA-TATE) IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE TUMOR
Phase 1/2Authorised not given Single-arm open-label phase I/II study in children and adolescents of 177Lu-DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptor (SSTR) (LuPARPed).
Phase 2Authorised not given EORTC 2334-BTG: [177Lu]Lu-DOTATATE for recurrent MENingioma (LUMEN-1): a randomized phase II study
Phase 2Authorised not given "Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases" "LUTARTERIAL"
Phase 1Ended not given A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing somatostatin receptors
Phase 1/2Authorised not given Randomized Interval Assessment trial of Lu177-Dotatate every 8 versus every 16 weeks in slowly progressive G1-2 advanced midgut neuroendocrine tumors (NETs) to Lower TOxicity.
Phase 3Authorised not given Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia – a multi-center, prospective, open-label, two-arm parallel group, randomized, controlled, phase III study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lu-DOTA-TATE

Following is part of Solo: you see every change to Lu-DOTA-TATE the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in